Physician profile
Pascal E Gaudreault
NPI 1811982754
$7,633.91
in general payments reported to CMS, 2019-2025
48 companies · $1,296 in 2025
The $1,296 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $665 · 2021: $901 · 2022: $941 · 2023: $1,267 · 2024: $1,833 · 2025: $1,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,387 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,387.04 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,026.30 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $996.15 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $794.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $788.54 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Pfizer INC. | $554.83 | 2019-2025 | |
| Glaxosmithkline, LLC. | $475.91 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $259.51 | 2019-2025 | Spravato, Xarelto |
| Sumitomo Pharma America, INC. | $233.93 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.23 | 2019-2025 | Jardiance |
| Amgen INC. | $199.16 | 2019-2025 | Otezla, Repatha, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $186.10 | 2019-2025 | Trintellix |
| Amarin Pharma, INC. | $170.18 | 2019-2022 | |
| Astellas Pharma US INC | $156.61 | 2020-2024 | Veozah |
| Merck Sharp & Dohme LLC | $141.62 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Exact Sciences Corporation | $130.62 | 2023-2025 | Cologuard Collection Kit |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pascal Gaudreault listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.